Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 74-78

  de Luis, D A ^a   Aller, R ^b   Izaola, O ^a   Gonzalez Sagrado, M ^a   Conde, R ^a   Gonzalez, J M ^b  

^a Medicine School   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Hypocaloric diet; Insulin resistance; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD PRESSURE; BODY MASS INDEX; BODY SIZE; DIET, REDUCING; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPIDS; OBESITY;

EID: 37549035945     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.07.015     Document Type: Article

References (27)

1. Ludwig J., Viggiano T.R., McGill D.B., and OhBJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc. 55 (1980) 434-438
2. Kral J.G., Schaffner F., Pierson R.N., and Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 42 (1993) 548-551
3. Chitturi S., Abeygunasekera S., Farell G.C., Holmes-Walker J., Hui M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002) 373-379
4. Marceau P., Biron S., Hould F.S., Marceau S., Simard S., Thung S.N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 84 (1999) 1513-1517
5. Drenick W.J., Simmon F., and Murphy J.F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N. Eng. J. Med. 282 (1970) 829-834
6. Andersen T., Gluud C., Franzmann M.B., and Christoffersen P. Hepatic effects of dietary weight loss in morbidity obese subjects. J. Hepatol. 12 (1991) 224-229
7. Rozental P., Biava C., Spencer H., and Zimmermann H.J. Liver morphology and function tests in obesity and during total starvation. Am. J. Dig. Dis. 12 (1967) 198-208
8. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J. Hepatol. 43 (2005) 1060-1066
9. Mathews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., and Treacher Df. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-414
10. Pichard C., Slosman D., Hirschel B., and Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. Clin. Res. 41 (1993) 53a
11. J. Mataix, M. Mañas, Tablas de composición de alimentos españoles, University of Granada, 2003.
12. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 18 (2001) 1343-1350
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N. Engl. J. Med. 6 346 (2002) 393-403
14. Chitturi S., Abeygunasekera S., Farrell G., and Holmes-Walker J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 73 (2002) 373-378
15. Marchesini G., Brizi M., Morselli-Labate A., Bianchi G., Bugianesi E., and McCullough A.J. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107 (1999) 450-454
16. Sanyal A.J., Campbell Sargent C., Mirshashi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
17. Rashid M., and Roberts E.A. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 30 (2000) 48-53
18. Daniel S., Ben Menachem T., Vasudevan G., Ma C.K., and Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am. J. Gastroenterol. 94 (1999) 3010-3014
19. Venturi C., Zoppini G., Zamboni C., and Muggeo M. Insulin sensivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr. Metab. Cardiovasc. Dis. 14 (2004) 200-204
20. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004) 147-152
21. Yesilova Z., Ozata M., Oktenli C., Bagci S., and Ozcan A. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am. J. Gastroenterol. 100 (2005) 842-849
22. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 15 358 (2001) 893-894
23. Lieber C.S., Leo M.A., Mak K.M., Xu Y., and cao Q. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem. Biophys. Res. Commun. 12 315 (2004) 699-703
24. Harrison S.A., Fincke C., Helsinki D., Torgerson S., and Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment. Pharmacol. Ther. 20 (2004) 623-628
25. ZelberSagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., et al. A double blind randomized placebo controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4 (2006) 639-644
26. Sabuncu T., Nazligul Y., Karaoglanoglu M., Ucar E., and Kilic F.B. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Am. J. Gastroenterol. 12 (2003) 189-192
27. Abdelmalek M., Ludwig J., and Lindor K.D. Two cases from the spectrum of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 20 (1995) 127